Cerity Partners LLC Raises Position in Haleon plc (NYSE:HLN)

Cerity Partners LLC increased its holdings in shares of Haleon plc (NYSE:HLN - Free Report) by 23.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 576,533 shares of the company's stock after purchasing an additional 109,311 shares during the quarter. Cerity Partners LLC's holdings in Haleon were worth $6,100,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its position in shares of Haleon by 41.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 203,583 shares of the company's stock worth $2,154,000 after buying an additional 59,719 shares during the last quarter. Banco Santander S.A. raised its stake in Haleon by 54.0% during the 3rd quarter. Banco Santander S.A. now owns 129,200 shares of the company's stock worth $1,367,000 after acquiring an additional 45,300 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Haleon in the third quarter valued at $1,794,000. King Luther Capital Management Corp acquired a new position in Haleon in the third quarter valued at $158,000. Finally, Prospera Private Wealth LLC purchased a new position in shares of Haleon during the third quarter worth about $57,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Stock Performance

HLN stock traded up $0.13 during trading on Thursday, hitting $9.72. The company had a trading volume of 5,935,717 shares, compared to its average volume of 5,314,855. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80. The firm has a 50-day moving average price of $9.95 and a 200-day moving average price of $9.41. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a market cap of $44.00 billion, a PE ratio of 28.59, a price-to-earnings-growth ratio of 2.89 and a beta of 0.30.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on HLN. Berenberg Bank initiated coverage on Haleon in a report on Tuesday, August 6th. They issued a "buy" rating for the company. Morgan Stanley boosted their price objective on Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a research note on Friday, September 20th. UBS Group upgraded shares of Haleon to a "strong-buy" rating in a research report on Tuesday, October 1st. Finally, The Goldman Sachs Group cut shares of Haleon from a "buy" rating to a "neutral" rating in a report on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Haleon has an average rating of "Buy" and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.